Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rth2.12121 http://scihub22266oqcxt.onion/10.1002/rth2.12121 C6046599!6046599 !30046758     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\30046758 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Res+Pract+Thromb+Haemost 2018 ; 2 (3 ): 529-534 Nephropedia Template TP {{tp|p=30046758 |t=2018. Extended anticoagulation for unprovoked venous thromboembolism |pdf=|usr=}}{{30046758 }} gab.com Text Extended anticoagulation for unprovoked venous thromboembolism JO: Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=30046758 #FOAvip After completing anticoagulation therapy for acute venous thromboembolism (VTE), patients with unprovoked VTE are at increased risk of recurrent thrombotic events. Recent studies suggest a risk of nearly 10% in the first year after stopping anticoagulants and 30% at 8 years. Therefore, it is important to consider extended anticoagulation for secondary prevention in these high-risk patients. While several oral anticoagulants are available for this purpose, there is limited information available regarding the optimal agent to minimize bleeding risks and maximize efficacy at VTE prevention. This review article summarizes the evidence available for Vitamin-K antagonists (VKAs) and direct oral anticoagulants (DOACs) for extended treatment of VTE. We also introduce the COVET trial, the first head-to-head comparison of VKAs to DOACs, rivaroxaban and apixaban, for extended management of unprovoked VTE. Twit Text FOAVip Extended anticoagulation for unprovoked venous thromboembolism ????Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=30046758 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30046758 #FOAvip English Wikipedia <ref>{{Cite pmid|30046758 }}</ref> Extended anticoagulation for unprovoked venous thromboembolism #MMPMID30046758 Castellucci LA ; de Wit K ; Garcia D ; Ortel TL ; Le Gal G Res Pract Thromb Haemost 2018[Jul]; 2 (3 ): 529-534 PMID30046758 show ga After completing anticoagulation therapy for acute venous thromboembolism (VTE), patients with unprovoked VTE are at increased risk of recurrent thrombotic events. Recent studies suggest a risk of nearly 10% in the first year after stopping anticoagulants and 30% at 8 years. Therefore, it is important to consider extended anticoagulation for secondary prevention in these high-risk patients. While several oral anticoagulants are available for this purpose, there is limited information available regarding the optimal agent to minimize bleeding risks and maximize efficacy at VTE prevention. This review article summarizes the evidence available for Vitamin-K antagonists (VKAs) and direct oral anticoagulants (DOACs) for extended treatment of VTE. We also introduce the COVET trial, the first head-to-head comparison of VKAs to DOACs, rivaroxaban and apixaban, for extended management of unprovoked VTE. äExtended anticoagulation for unprovoked venous thromboembolism (epmc).pdf DeepDyve Pubget Overpricing